New data has revealed a long-term response in patients with advanced non-small cell lung cancer (NSCLC) taking Rybrevant (amivantamab).
The CHRYSALIS study is evaluating amivantamab in patients with advanced non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on prior platinum-based chemotherapy.
Data from the study was presented at the 2023 European Lung Cancer Congress (ELCC) taking place from March 29 – April 1 in Copenhagen, Denmark.
Investigators assessed the efficacy and safety of amivantamab in patients with NSCLC and EGFR exon 20 insertion mutations, who had progressed on prior platinum-based chemotherapy, and were treated at the recommended Phase II dose of 1050mg.
“Despite treatment advances, patients with advanced NSCLC with EGFR exon 20 insertion mutations continue to face poor clinical outcomes,” said Martin Vogel, EMEA Therapeutic Area Lead Oncology, Janssen-Cilag GmbH. “These insights reinforce the potential of amivantamab as a targeted and effective option for these patients, and our commitment to lead the way in precision medicine approaches, whereby we are better able to identify the distinct patient populations most likely to benefit from specific treatments.”
Trial results
After a median follow-up of 19.2 months, the median overall survival (OS) with amivantamab treatment was 23 months with a two-year OS rate of 47%. The investigator-assessed overall response rate (ORR) was 37%, and median progression-free survival (PFS) of 6.9 months.
Across subgroups, treatment with amivantamab resulted in consistent efficacy across post-platinum patients with EGFR exon 20 insertion mutations, including the elderly, regardless of prior therapies or response to prior platinum chemotherapy.
Forty-eight patients (42%) had sustained clinical response measured by ORR on amivantamab for at least 12 cycles. The median duration of treatment was 7.5 months and treatment is ongoing in 15 patients (13%) who have received amivantamab for a median of 2.6 years. Of these patients, seven are progression-free and eight are receiving treatment beyond progression.
“With these new data, amivantamab showed long-term consistent efficacy regardless of prior therapies or response to prior platinum chemotherapy,” said Pilar Garrido, Associate Professor of Medical Oncology at Universidad de Alcalá, Head of Medical Oncology Department at the University Hospital Ramón y Cajal in Madrid, Spain and principal investigator. “Due to the aggressive nature of NSCLC with EGFR exon 20 insertion mutations, treatment with targeted therapies is an important consideration when identifying a treatment option for patients.”
